Cargando…

Nucleic Acid Hybrids as Advanced Antibacterial Nanocarriers

Conventional antibiotic therapy is often challenged by poor drug penetration/accumulation at infection sites and poses a significant burden to public health. Effective strategies to enhance the therapeutic efficacy of our existing arsenal include the use of nanoparticulate delivery platforms to impr...

Descripción completa

Detalles Bibliográficos
Autores principales: Obuobi, Sybil, Škalko-Basnet, Nataša
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408145/
https://www.ncbi.nlm.nih.gov/pubmed/32650506
http://dx.doi.org/10.3390/pharmaceutics12070643
_version_ 1783567770250641408
author Obuobi, Sybil
Škalko-Basnet, Nataša
author_facet Obuobi, Sybil
Škalko-Basnet, Nataša
author_sort Obuobi, Sybil
collection PubMed
description Conventional antibiotic therapy is often challenged by poor drug penetration/accumulation at infection sites and poses a significant burden to public health. Effective strategies to enhance the therapeutic efficacy of our existing arsenal include the use of nanoparticulate delivery platforms to improve drug targeting and minimize adverse effects. However, these nanocarriers are often challenged by poor loading efficiency, rapid release and inefficient targeting. Nucleic acid hybrid nanocarriers are nucleic acid nanosystems complexed or functionalized with organic or inorganic materials. Despite their immense potential in antimicrobial therapy, they are seldom utilized against pathogenic bacteria. With the emergence of antimicrobial resistance and the associated complex interplay of factors involved in antibiotic resistance, nucleic acid hybrids represent a unique opportunity to deliver antimicrobials against resistant pathogens and to target specific genes that control virulence or resistance. This review provides an unbiased overview on fabricating strategies for nucleic acid hybrids and addresses the challenges of pristine oligonucleotide nanocarriers. We report recent applications to enhance pathogen targeting, binding and control drug release. As multifunctional next-generational antimicrobials, the challenges and prospect of these nanocarriers are included.
format Online
Article
Text
id pubmed-7408145
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74081452020-08-25 Nucleic Acid Hybrids as Advanced Antibacterial Nanocarriers Obuobi, Sybil Škalko-Basnet, Nataša Pharmaceutics Review Conventional antibiotic therapy is often challenged by poor drug penetration/accumulation at infection sites and poses a significant burden to public health. Effective strategies to enhance the therapeutic efficacy of our existing arsenal include the use of nanoparticulate delivery platforms to improve drug targeting and minimize adverse effects. However, these nanocarriers are often challenged by poor loading efficiency, rapid release and inefficient targeting. Nucleic acid hybrid nanocarriers are nucleic acid nanosystems complexed or functionalized with organic or inorganic materials. Despite their immense potential in antimicrobial therapy, they are seldom utilized against pathogenic bacteria. With the emergence of antimicrobial resistance and the associated complex interplay of factors involved in antibiotic resistance, nucleic acid hybrids represent a unique opportunity to deliver antimicrobials against resistant pathogens and to target specific genes that control virulence or resistance. This review provides an unbiased overview on fabricating strategies for nucleic acid hybrids and addresses the challenges of pristine oligonucleotide nanocarriers. We report recent applications to enhance pathogen targeting, binding and control drug release. As multifunctional next-generational antimicrobials, the challenges and prospect of these nanocarriers are included. MDPI 2020-07-08 /pmc/articles/PMC7408145/ /pubmed/32650506 http://dx.doi.org/10.3390/pharmaceutics12070643 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Obuobi, Sybil
Škalko-Basnet, Nataša
Nucleic Acid Hybrids as Advanced Antibacterial Nanocarriers
title Nucleic Acid Hybrids as Advanced Antibacterial Nanocarriers
title_full Nucleic Acid Hybrids as Advanced Antibacterial Nanocarriers
title_fullStr Nucleic Acid Hybrids as Advanced Antibacterial Nanocarriers
title_full_unstemmed Nucleic Acid Hybrids as Advanced Antibacterial Nanocarriers
title_short Nucleic Acid Hybrids as Advanced Antibacterial Nanocarriers
title_sort nucleic acid hybrids as advanced antibacterial nanocarriers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408145/
https://www.ncbi.nlm.nih.gov/pubmed/32650506
http://dx.doi.org/10.3390/pharmaceutics12070643
work_keys_str_mv AT obuobisybil nucleicacidhybridsasadvancedantibacterialnanocarriers
AT skalkobasnetnatasa nucleicacidhybridsasadvancedantibacterialnanocarriers